2. Anti-infection Cell Cycle/DNA Damage
  3. Influenza Virus DNA/RNA Synthesis
  4. Onradivir

Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection.

For research use only. We do not sell to patients.

Onradivir

Onradivir Chemical Structure

CAS No. : 2200336-20-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of Onradivir:

Onradivir Related Antibodies

Top Publications Citing Use of Products

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection[1][2].

IC50 & Target

RNA Polymerase

 

In Vitro

Onradivir (0.457-1000 nM; 24 h post-6-hour transfection) potently inhibits influenza A virus polymerase activity in HEK293T cells, with a mean IC50 of 0.562 nM[2].
Onradivir (0.17-10,000 nM) does not inhibit most tested human kinases at concentrations up to 10,000 nM, with only weak activity against Aurora A kinase (IC50 = 527 nM)[2].
Onradivir (0.0005-100 μM; 2-5 days) potently inhibits replication of wild-type, Oseltamivir (HY-13317)-resistant, and Baloxavir (HY-109025A)-resistant influenza A strains in MDCK cells (EC50 0.012-0.063 nM) with high selective index, and shows weak activity against HRV-1B (EC50 7.88 μM) in H1 HeLa cells[2].
Onradivir (48 h post-virus infection) potently inhibits replication of highly pathogenic avian influenza H7N9 and H5N6 viruses in MDCK cells, with IC50 values ranging from 0.245-0.777 nM[2].
Onradivir (10 μM; 3 days) does not inhibit HCV genotype 1b replicon replication or cause cytotoxicity at concentrations up to 10 μM[2].
Onradivir (0.16-40 μM; 1 min per concentration) does not significantly inhibit hERG potassium channel function in CHO cells at concentrations up to 40 μM (IC50 >40 μM)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Onradivir Related Antibodies
Parmacokinetics
Species Dose Route CL T1/2 Vdss AUC0-last Cmax Tmax Bioavailability
Rat[2] 3 mg/kg i.v. 12.9 mL/min/kg 2.11 h 0.508 L/kg 3950 ng·h/mL / / /
Rat[2] 3 mg/kg p.o. / / / 899 ng·h/mL 661 ng/mL / 22.8 %
Rat[2] 15 mg/kg p.o. / / / 7490 ng·h/mL 5620 ng/mL / /
Rat[2] 75 mg/kg p.o. / / / 77700 ng·h/mL 17200 ng/mL / /
Dog[2] 1 mg/kg i.v. 25.8 mL/min/kg 0.457 h 0.470 L/kg 791 / / /
Dog[2] 1 mg/kg p.o. / / / 211 ng·h/mL 292 ng/mL 0.458 h 26.7 %
Dog[2] 5 mg/kg p.o. / / / 1210 ng·h/mL 1450 ng/mL 0.542 h /
Dog[2] 15 mg/kg p.o. / / / 5030 ng·h/mL 5800 ng/mL 0.458 h /
In Vivo

Onradivir (ZSP1273) (3-30 mg/kg; p.o.; twice daily; days 1-2 to days 1-4) dose-dependently reduces lung viral titers and supports body weight recovery in influenza A virus WSN/33 (H1N1)-infected female BALB/c mice when administered starting 36 h post-infection, with the 30 mg/kg dose reducing viral titers below the limit of detection[2].
Onradivir (ZSP1273) (10 mg/kg; p.o.; twice daily; 7 days) provides 100% survival when administered 4 h pre-infection, improves survival when administered 48 h post-infection, provides partial survival when administered 72 h post-infection, and extends time to death when administered 96 h post-infection in influenza A virus WSN/33 (H1N1)-infected female BALB/c mice[2].
Onradivir (ZSP1273) (30-100 mg/kg; p.o.; twice daily; 7 days) provides 100% survival at 30 mg/kg, and provides high survival with minimal deaths at 100 mg/kg, when administered starting 48 h post-infection in influenza A virus WSN/33 (H1N1)-infected female BALB/c mice[2].
Onradivir (ZSP1273) (25 mg/kg; p.o.; twice daily; 5 days) significantly reduces nasal lavage viral load and maintains stable body weight in influenza A virus/California/07/2009 (H1N1)-infected female ferrets when administered starting 4 h pre-infection[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, SPF grade, 6-7 weeks old, 16-18 g, intranasal inoculation with influenza A virus WSN/33 (H1N1))[2]
Dosage: 3 mg/kg (day 5 endpoint); 10 mg/kg (day 3 endpoint; day 5 endpoint); 30 mg/kg (day 5 endpoint)
Administration: p.o.; twice daily; days 1-2 (day 3 endpoint); days 1-4 (day 5 endpoint)
Result: Reduced lung viral titers.
Enabled mice in the 30 mg/kg group to begin regaining body weight on day 4.
Enabled mice in the 10 mg/kg group to begin regaining body weight on day 5.
Animal Model: BALB/c (female, SPF grade, 6-7 weeks old, 16-18 g, intranasal inoculation with influenza A virus WSN/33 (H1N1))[2]
Dosage: 10 mg/kg
Administration: p.o.; twice daily; 7 consecutive days; first dose at 4 h pre-infection; first dose at 48 h post-infection; first dose at 72 h post-infection; first dose at 96 h post-infection
Result: Maintained a 100% survival rate through day 14 and prevented significant body weight loss when dosed at 4 h pre-infection.
Improved survival rate compared to vehicle and supported body weight recovery starting after nadir weight loss when dosed at 48 h post-infection.
Resulted in a 25% survival rate.
Molecular Weight

440.45

Formula

C22H22F2N6O2
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

FC1=CN=C2C(C(C3=NC(N[C@@H]4[C@H](C5CCC4CC5)C(O)=O)=C(F)C(C6CC6)=N3)=NN2)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (227.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2704 mL 11.3520 mL 22.7041 mL
5 mM 0.4541 mL 2.2704 mL 4.5408 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic

    This protocol yields a clear solution of 2.5 mg/mL.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic

    This protocol yields a clear solution of 2.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.53%

SDS (254 KB)

COA (255 KB) HNMR (137 KB) LCMS (101 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2704 mL 11.3520 mL 22.7041 mL 56.7601 mL
5 mM 0.4541 mL 2.2704 mL 4.5408 mL 11.3520 mL
10 mM 0.2270 mL 1.1352 mL 2.2704 mL 5.6760 mL
15 mM 0.1514 mL 0.7568 mL 1.5136 mL 3.7840 mL
20 mM 0.1135 mL 0.5676 mL 1.1352 mL 2.8380 mL
25 mM 0.0908 mL 0.4541 mL 0.9082 mL 2.2704 mL
30 mM 0.0757 mL 0.3784 mL 0.7568 mL 1.8920 mL
40 mM 0.0568 mL 0.2838 mL 0.5676 mL 1.4190 mL
50 mM 0.0454 mL 0.2270 mL 0.4541 mL 1.1352 mL
60 mM 0.0378 mL 0.1892 mL 0.3784 mL 0.9460 mL
80 mM 0.0284 mL 0.1419 mL 0.2838 mL 0.7095 mL
100 mM 0.0227 mL 0.1135 mL 0.2270 mL 0.5676 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Onradivir Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Onradivir2200336-20-3ZSP1273ZSP 1273ZSP-1273Influenza VirusDNA/RNA Synthesisinfluenza A virus RNA polymerase PB2 subunitMDCK cellsH1 HeLa cellsCHO cellsinfluenza A virusferretshighly pathogenic avian influenza A virusHepG2.2.15 cellsHEK293T cellsBALB/c miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Onradivir
Cat. No.:
HY-145586
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.